Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole

Stefania Bellone; Hemendrah R Shah; Jesse K McKenney; Pamela J B Stone; Alessandro D Santin

doi:10.1016/j.ajog.2008.04.012

Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole

Am J Obstet Gynecol. 2008 Sep;199(3):e7-e10. doi: 10.1016/j.ajog.2008.04.012. Epub 2008 Jun 12.

Authors

Stefania Bellone¹, Hemendrah R Shah, Jesse K McKenney, Pamela J B Stone, Alessandro D Santin

Affiliation

¹ Department of Obstetrics and Gynecology, Division of Gynecologic Oncology Yale University School of Medicine, New Haven, CT 06520-8063, USA.

PMID: 18550023
DOI: 10.1016/j.ajog.2008.04.012

Abstract

Recurrent/metastatic endometrial adenocarcinoma that is not amenable to cure with local or regional therapy and/or chemotherapy represents a discouraging clinical entity for the clinician. We report the case of 58-year-old woman with recurrent endometrial carcinoma that was resistant to chemotherapy that was treated successfully with the aromatase inhibitor anastrozole.

Publication types

Case Reports

MeSH terms

Adenocarcinoma / diagnostic imaging
Adenocarcinoma / drug therapy*
Adenocarcinoma / metabolism
Adenocarcinoma / pathology
Adenocarcinoma / secondary
Anastrozole
Aromatase Inhibitors / therapeutic use*
Endometrial Neoplasms / diagnostic imaging
Endometrial Neoplasms / drug therapy*
Endometrial Neoplasms / metabolism
Endometrial Neoplasms / pathology
Female
Humans
Immunohistochemistry
Lung Neoplasms / secondary
Middle Aged
Neoplasm Recurrence, Local / diagnostic imaging
Neoplasm Recurrence, Local / drug therapy*
Nitriles / therapeutic use*
Receptors, Estrogen / metabolism
Tomography, X-Ray Computed
Triazoles / therapeutic use*

Substances

Aromatase Inhibitors
Nitriles
Receptors, Estrogen
Triazoles
Anastrozole